Cisco, Chang & Charlie Part 3

by DrKSSMDPhD | September 19, 2017 8:42 am

This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.

Source URL: https://www.stockgumshoe.com/2017/09/cisco-chang-charlie-part-3/


999 responses to “Cisco, Chang & Charlie Part 3”

  1. rmwrip123 says:

    $XXII

    I found this article today.

    https://finance.yahoo.com/news/phase-iii-study-using-22nd-103000616.html

    I just attended the Wisconsin Society of Addiction Medicine annual conference. One of the speakers was Mike Fiore. He heads the University of Wisconsin Center for Tobacco Research and Intervention and has been very involved with policy at the national level. He stated there is no doubt that the FDA will be mandating a dramatic and quick lowering of nicotine levels in tobacco in the near future. This could be a great thing for overall public health. A large majority of my addiction patients still smoke/chew and I spend a lot of time helping them reduce/quit. A true addict will find other sources of nicotine but Iā€™m sure this initiative will help.
    It looks like this company is also trying to produce strains of very low THC content cannabis. Smoked cannabis will never be improved but edibles?

    Rick

  2. smanuelm says:

    $ABVX np
    Abivax $ABVX ABX464-101 phase 2a in UC – recruitment now open, topline data forecasted H2 2018
    thanks @BiotechRadar
    https://t.co/xzmu8n5H84

  3. cw99 says:

    $CWBR
    Really??? ASK just went from 4.23 to 5.25 in one minute.

  4. yelpik says:

    Careful gang it has now popped 2 bucks and they have nothing even in phase 1 yet. Should have plenty of time to buy when settles back down.

  5. Cleveland says:

    $CWBR

    CohBar Vision and Background

    https://www.youtube.com/watch?v=z4g1DqqTHxE

  6. yelpik says:

    Great call today. Thanks Doc and Cleveland. Can’t thank you enough for your time.

  7. dianelu says:

    $CWBR MOTS-c Targets the Methionine-Folate Cycle; MOTS-c shares many effects with the antifolate drug methotrexate. See:

    http://www.cell.com/cell-metabolism/fulltext/S1550-4131(15)00061-3

  8. mvssysprog says:

    $RPRX

    Does anyone know what is going on with Repros Therapeutics today? It is up nearly 60% with nearly 35x normal 10 day volume. There is no news at all on the wires. Dave

  9. peterk says:

    Conference call
    Couldn’t connect me from Germany
    Have to wait the recording
    Peter

  10. thinairmony says:

    $CAPR NP- LA JOLLA, Calif., Oct. 6, 2017 /PRNewswire/ — Capricor Therapeutics, Inc. (NASDAQ: CAPR), in a poster presentation at the Alliance for Regenerative Medicine’s Cell and Gene Meeting on the Mesa, provided data which support the peripheral intravenous (IV) administration method the company plans to use in HOPE-2, its planned next clinical trial of its lead investigational product, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD).
    CAP-1002 consists of allogeneic cardiosphere-derived cells (CDCs), whose mechanism of action is immunomodulatory and anti-fibrotic. CDCs have been shown to generate new muscle cells in preclinical models.

  11. jmarkar says:

    After the really stimulating conference call… did a little digging for additional self-education. I thought this article might be a relevant corollary to the discussion.

    https://mitochondrialdiseasenews.com/2017/09/25/damaged-mitochondria-linked-to-age-related-diseases-ucla-researchers-find/

  12. fred says:

    Any idea why Capr is plunging?

  13. ajgormican says:

    I shall take all Doc has taught me and trudge forward through the thick and thin weary eyed but unforgotten. Together we rise, but divided we fall. Godspeed Gummies.

  14. fred says:

    Any updates on CAPR?